The performance of companies tied to Sildenafil's past presents a complex investment landscape. While the initial surge generated substantial returns , generic alternatives have significantly diminished market share . Investing in connected pharmaceutical companies now requires a discerning assessment of proprietary rights , evolving medical shifts